AtheroGenics, Inc., (AGIXQ) Plan Confirmed...
June 10, 2009;
The U.S. Bankruptcy Court issued an order confirming AtheroGenics'Second Amended Plan, as modified. Pursuant to the Plan, all property of the Debtor and its estate, including cash, will vest automatically in the post-confirmation Debtor and the liquidating fund on the effective date, free and clear of all liens, claims, and interests and without the need for the execution or delivery of any instruments of assignment, for the express purpose of, among other things, allowing the liquidating agent to make distributions to holders of allowed claims pursuant to the terms and conditions of the Plan. Without limiting the foregoing, the post-confirmation Debtor will be vested with all of the Debtor's previously unsold remaining assets (including its causes of action), which will be administered, liquidated, prosecuted, settled and enforced under the direction and control of the liquidating agent. This research-based pharmaceutical company filed for Chapter 11 protection on October 15, 2008, listing total pre-petition assets of $103 million.